202 298

Cited 0 times in

잠복 결핵 검사에 음성 반응을 보인 궤양성 대장염 환자에서 발생한 Infliximab 연관 다제내성 파종성 결핵

Other Titles
 Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis 
 전유경  ;  천재영  ;  강은애  ;  이현정  ;  임종필  ;  김주성 
 Korean Journal of Gastroenterology, Vol.74(3) : 168-174, 2019 
Journal Title
Korean Journal of Gastroenterology
Issue Date
Inflammatory bowel diseases ; Infliximab ; Tuberculosis, multidrug-resistant ; Colitis, ulcerative
Anti-tumor necrosis factor (anti-TNF) is an effective biological agent for the treatment of moderate-to-severe active ulcerative colitis
(UC) refractory to conventional therapy. On the other hand, anti-TNF therapy is strongly associated with a potential risk of tuberculosis
(TB). Active TB is a critical complication that makes it difficult to treat patients who require anti-TNF for the treatment of UC refractory
to conventional therapy. Based on the clinical guidelines, patients with inflammatory bowel disease (IBD) are strongly recommended
to screen for latent TB before anti-TNF administration. Considering the possibility of active or reactivated TB related to anti-TNF therapy,
all patients with IBD should be monitored closely for TB during anti-TNF therapy, irrespective of the screening results for latent TB.
In particular, the risk of anti-TNF-related multidrug-resistant TB (MDR-TB) in patients with IBD has not been elucidated. This paper
reports the first case of disseminated MDR-TB that developed in a UC patient receiving infliximab despite the negative evaluation
for latent TB screening.
Files in This Item:
T201904535.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Chun, Jaeyoung(천재영) ORCID logo https://orcid.org/0000-0002-4212-0380
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.